Case Studies in Movement Disorders

Virgilio Gerald H. Evidente; John N. Caviness; Charles H. Adler

doi:10.1055/s-2003-814739

Seminars in Neurology, Inhaltsverzeichnis

Semin Neurol 2003; 23(3): 277-284
DOI: 10.1055/s-2003-814739

Case Studies in Movement Disorders

Virgilio Gerald H. Evidente¹ , John N. Caviness² , Charles H. Adler³

¹Assistant Professor, Movement Disorders Division, Department of Neurology, Mayo Clinic, Scottsdale, Arizona
²Associate Professor, Movement Disorders Division, Department of Neurology, Mayo Clinic, Scottsdale, Arizona
³Professor, Movement Disorders Division, Department of Neurology, Mayo Clinic, Scottsdale, Arizona

Abstract

ABSTRACT

Six cases representing the most commonly encountered movement disorders-restless legs syndrome with periodic limb movements, tics, myoclonus, chorea, essential tremor, and cervical dystonia-are presented. Discussion of each case focuses on a practical approach to recognizing the important clinical features of each movement disorder as well as the current therapeutic options. A detailed discussion of botulinum toxin follows the case on cervical dystonia, focusing on its mechanism of action, clinical indications, side effects, and dosing.

KEYWORDS

Restless legs syndrome - Tourette's syndrome - myoclonus - Huntington's disease - essential tremor - dystonia - botulinum toxin

Volltext

Referenzen

REFERENCES

1 Walters A S. The International Restless Legs Syndrome Study Group: toward a better definition of the restless legs syndrome. Mov Disord . 1995; 10 634-642
2 Allen R P, Pichietti D, Hening W A. et al . Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology: a report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med . 2003; 4 101-119
3 Evidente V GH, Adler C H. How to help patients with restless legs syndrome: discerning the indescribable and relaxing the restless. Postgrad Med . 1999; 105 59-74
4 Evidente V GH, Esteban R, Domingo F, Carbajal L, Parazo M. Piribedil as an adjunct to levodopa in advanced Parkinson's disease: the Asian experience (in press). Parkinsonism Relat Disord 2003.
5 Evidente V GH, Adler C H, Caviness J N, Gwinn-Hardy K. Amantadine is beneficial in restless legs syndrome. Mov Disord . 2000; 15 324-327
6 Evidente V GH. Is it a tic or Tourette's?. <~>Clues for differentiating simple from more complex tic disorders. Postgrad Med . 2000; 108 175-182
7 Sallee F R, Kurlan R, Goetz C G. et al . Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry . 2000; 39 292-299
8 Jimenez-Jimenez F J, Garcia-Ruiz P J. Pharmacologic options for the treatment of Tourette's disorder. Drugs . 2001; 61 2207-2220
9 Kwak C H, Hanna P A, Jankovic J. Botulinum toxin in the treatment of tics. Arch Neurol . 2000; 57 1190-1193
10 Caviness J N. Myoclonus. Mayo Clin Proc . 1996; 71 679-688
11 Marsden C D, Hallett M, Fahn S. The nosology and pathophysiology of myoclonus. In: Marsden CD, Fahn S, eds. Movement Disorders London: Butterworth 1982: 196-248
12 Brown P. Myoclonus: a practical guide to drug therapy. CNS Drugs . 1995; 3 22-29
13 Shoulson I. On chorea. Clin Neuropharmacol . 1986; 9 (suppl 2) S85-S99
14 Weiner W J, Lang A E. Huntington's disease. In: Movement Disorders, a Comprehensive Survey Mount Kisco, NY: Futura 1989: 293-346
15 Hubble J P. Essential tremor: diagnosis and treatment. In: Adler CH, Ahlskog JE, eds. Parkinson's Disease and Movement Disorders: Diagnosis and Treatment Guidelines for the Practicing Physician Totowa, NJ: Humana Press 2000: 283-295
16 Adler C H. Differential diagnosis of Parkinson's disease. Med Clin North Am . 1999; 83 349-367
17 Adler C H. Botulinum toxin treatment of movement disorders. In: Adler CH, Ahlskog JE, eds. Parkinson's Disease and Movement Disorders: Diagnosis and Treatment Guidelines for the Practicing Physician Totowa, NJ: Humana Press 2000: 385-394
18 Tarsy D. Dystonia. In: Adler CH, Ahlskog JE, eds. Parkinson's Disease and Movement Disorders: Diagnosis and Treatment Guidelines for the Practicing Physician Totowa, NJ: Humana Press 2000: 297-319
19 Johnson E A. Biomedical aspects of botulinum toxin. J Toxicol Toxin Rev . 1999; 18 1-15